Blog

August 14, 2023 – Everest Pharma proudly announces the launch of CRAVACIN, the FDA-approved generic version of SOTYKTU, marking a major advancement in the treatment of moderate-to-severe plaque psoriasis. CRAVACIN (Generic SOTYKTU) offers patients a more affordable and accessible alternative to the branded drug, specifically benefiting those managing plaque psoriasis. Deucravacitinib is a TYK2 (tyrosine […]

Psoriasis affects over 8 million individuals in the United States. The most prevalent form is plaque psoriasis, which impacts 80 to 90 percent of those diagnosed with the condition. This type of psoriasis is marked by inflamed, scaly patches of skin known as “plaques,” which can be itchy and sometimes painful. On lighter skin tones,

June 15, 2024 – Everest Pharma has announced the launch of Resiliva, the world’s first generic version of Resmetirom, marking a significant milestone in the treatment of metabolic and liver diseases. Resiliva is expected to provide an affordable and accessible alternative to the branded medication, particularly for patients suffering from non-alcoholic steatohepatitis (NASH) with liver

March 14, 2024- Today, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. “Previously, patients with NASH who also have notable liver scarring did not have a medication that could